Our data support previous findings in various cancer cell lines that p53 mutational status sensitizes cells to WEE1i treatment [109, 110] and here we provide a mechanistic explanation because CDK1/cyclin B1 protein levels and activity are increased in p53KO [100] exacerbating the DNA damage phenotype. The gene discussed is TP53; the disease is cancer.